Ergebnisse 1 - 3 von 3 :

  • pharmacokinetics x
  • Allgemeinmedizin, Innere Medizin x
  • Klinische Medizin x
  • Gastroenterologie x
Alle zurücksetzen
A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis

. VOIOSU T, BENGUŞ A, BĂLĂNESCU P, DINU R, VOIOSU A, BĂICUŞ C et al. Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and Serum tumor necrosis factor α in patients with ulcerative colitis. Rom J Intern Med. 2015; 53(3):253-60. 18. DOTAN I, RON Y, YANAI H, BECKER S, FISHMAN S, YAHAV L et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20(12):2247-59. 19. BRANDSE JF, MATHÔT RA, VAN

Open access
Novel Oral Anticoagulants, A Subject in Continuing Debate

, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. AmJ Emerg Med. 2016;34(11S):26-32. 14. Choo WK, Fraser S, Padfield G et al. Dabigatran improves the efficiency of an elective direct current cardioversion service. Br J Cardiol 2014;21:29–32. 15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. 16. Sakabe M, Yoshioka R, Fujiki A. Low APTT and BMI predicts the occurrence of ischemic stroke in patients with Atrial Fibrillation

Open access
The frequency of bone fractures among patients with chronic kidney disease not on dialysis: two-year follow-up

., AKITA W., KUYAMA T., TAKADA S., ASAI T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients – a single-center cohort study. Nephrol Dial Transplant 2012; 27 :345-51. 27. LIN JH. Bisphosponates: a review of their pharmacokinetic properties . Bone. 1996; 18 (2):75-85. 28. CONTR P., GUARNERI V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. The Oncologist.2004; 9 (Suppl 4): 28-37. 29. SHERRARD DJ., HERCZ G., PEI Y

Open access